Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Ferrari NV (RACE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Ferrari NV — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Ferrari NV trades at $374.72 (market cap $67.98B). The key difference: Ferrari NV is far larger — about 15.1× ACADIA Pharmaceuticals Inc.'s market cap, and Ferrari NV pays a 1.09% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | RACE | |
|---|---|---|
Market Cap | $4.49B | $67.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $517.65 |
52-Week Low | $20.06 | $314.63 |
Enterprise Value | $3.69B | $69.19B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Ferrari (RACE) trades at $386.99, up 0.52% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, a 22.19% net margin, and robust cash flow. Recent news highlights the company's ongoing share buyback program and strategic moves like the new V12 model and EV developments. Analyst sentiment remains positive with a $467.50 consensus target.
The outlook is favorable given Ferrari's pricing power and hybrid sales growth, but risks include EV market reception and economic sensitivity. Wall Street's strong buy consensus (72% buy ratings) supports upside potential, though high valuation multiples warrant caution amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
